Human time-restricted-eating trials show mixed short-term results—not slower aging

The bottom line

Restricting the daily eating window is not one standardized intervention. In three short randomized trials, outcomes changed with timing, calorie counseling and comparator. TREAT found no significant between-group weight benefit; an early-window trial found 2.3 kg more weight loss alongside energy restriction; and a 2025 trial found no added MRI visceral-fat benefit over Mediterranean-diet usual care.

None of these trials measured biological aging, durable healthspan, mortality or lifespan.

Why this matters

Animal fasting research, circadian biology and human weight-loss trials are often blended into one longevity story. But an earlier dinner, fewer calories, improved diet quality and a shorter eating window can occur together. A trial’s comparator determines which part of that bundle it can isolate.

What researchers did

TREAT assigned 116 adults to eat within noon–8 p.m. or follow consistent meal timing for 12 weeks without calorie targets. A 14-week Alabama trial assigned 90 adults receiving the same structured weight-loss counseling to an early eight-hour window or a window of at least 12 hours. A 2025 Spanish trial assigned 197 adults to Mediterranean-diet counseling alone or with early, late or self-selected eight-hour windows for 12 weeks.

What they found

In TREAT, the between-group weight difference was -0.26 kg (95% CI -1.30 to 0.78; p=0.63). In its 50-person in-clinic subset, appendicular lean-mass index declined more with time-restricted eating. The article has two corrections covering Figure 2 alignment/labels and clarification of messages delivered to participants.

In the 14-week trial, early timing produced 2.3 kg more weight loss (95% CI -3.7 to -0.9), but did not significantly improve the co-primary body-fat amount or fat-loss ratio. Diastolic blood pressure differed by -4 mm Hg; most other cardiometabolic measures were similar. In the 2025 trial, no timing group significantly reduced MRI visceral fat more than usual care.

How strong is the evidence?

These are randomized human trials, but they answer short, population-specific questions. The positive 14-week weight result occurred when both groups received energy restriction, and the estimated effect was comparable to an additional 214 kcal per day. The 2025 null result used active diet counseling. Mixed findings do not establish that timing never matters; they show why “time-restricted eating works” is too broad.

What this evidence does not show

It does not show slower epigenetic or biological aging, fewer late-life disabilities, lower mortality or longer life. It does not establish long-term adherence or separate every effect of timing from spontaneous calorie reduction. These trials also do not supply a universally safe eating schedule for people with diabetes, eating disorders, pregnancy, frailty, medication timing needs or other medical contexts.

Safety and conflicts

Durations were short and populations were selected. The 2025 trial reported no serious adverse events and five mild events, but that cannot establish rare or long-term safety. The 14-week study was NIH-supported; investigators disclosed an outside advisory role and institutional intellectual property related to food-intake measurement. The 2025 report disclosed unrelated lecture fees for one author.

What happens next

Longer trials should measure adherence, energy intake, diet quality, sleep, function and clinical outcomes while comparing matched calories and clearly defined early versus late windows. Aging claims need direct aging or meaningful health outcomes, not a short change in weight or one biomarker.